Saros Therapeutics
Saros Therapeutics’ proprietary nanoparticle technology addresses significant unmet needs in oncology and autoimmunity. The platform safely achieves innate immune cell targeting and initiates robust immune responses. The lead immuno-oncology program targets STING, overcoming challenges of prior products and showing curative therapeutic potential. With robust efficacy data, a wide therapeutic index, scalable manufacturing, and an experienced team, the company is raising capital to complete IND filing.
Contact Name:
Jennifer Chadwick
Contact Email:
Website:
https://www.sarostx.com/
City, State – Congressional District:
Riverwoods,
IL
–
10
Technology:
Drug
Funding:
Cancer (NCI)
NIH Projects:
NIH RePorter for
Saros Therapeutics
Sponsored Event(s):
Biotech Showcase | 2025
